Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).

Authors:

Sternberg C, Fizazi K, Saad F, et al.

Year

2020

Conference

ASCO Annual Meeting

Start Date

May 29

End Date

Jun 2